Use of wogonin in preparation of drug for treating chronic kidney disease

A technology of wogonin and chronic kidney disease, which is applied in the field of pharmaceuticals and can solve the problems of no reports of chronic kidney disease

Active Publication Date: 2013-09-11
SHANGHAI UNIV OF T C M
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the antitumor activity of wogonin is a research hotspot at home a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of wogonin in preparation of drug for treating chronic kidney disease
  • Use of wogonin in preparation of drug for treating chronic kidney disease
  • Use of wogonin in preparation of drug for treating chronic kidney disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 (medicine efficacy test of wogonin on unilateral ureteral ligation (UUO) model rats)

[0028] 1. Purpose of the test: To investigate whether wogonin can improve renal fibrosis in unilateral urinary catheter ligation (UUO) model rats.

[0029] 2. Test method:

[0030] 2.1. Animal grouping

[0031] They were randomly divided into 5 groups: 10 rats in the sham operation group, 10 rats in the model group, 10 rats in the losartan group, 10 rats in the low-dose wogonin group, and 10 rats in the high-dose wogonin group.

[0032] 2.2. Model making

[0033] Except for the sham operation group, the other 4 groups underwent unilateral ureteral ligation. The method was as follows: After the experimental rats were anesthetized with chloral hydrate (400 mg / kg) intraperitoneally, an incision was made in the left abdominal kidney area of ​​the rats, and the left side was separated with ophthalmic forceps. For the ureter, use No. 4 surgical thread to ligate the ureter at th...

Embodiment 2

[0063] Embodiment 2 (medicine efficacy test of wogonin on 5 / 6 nephrectomy model rats)

[0064] 1. Purpose of the test: To investigate whether wogonin can improve renal fibrosis in 5 / 6 nephrectomy model rats.

[0065] 2. Test method:

[0066] 2.1. Animal grouping, model making, drug administration and material collection

[0067] Rats ate standard food, drank water freely, and were adaptively fed for 1 week, and were randomly divided into 5 groups: 10 rats in the sham operation (Sham) group, 10 rats in the model group (5 / 6 nephrectomy), and 10 rats in the losartan group (20mg / kg) 10 rats, 10 rats in the wogonin low-dose (10 mg / kg) group, and 10 rats in the wogonin high-dose group (20 mg / kg) group.

[0068] Except for the sham operation group, the rest were used as the modeling group. Rats in the model group were anesthetized by intraperitoneal injection, and the rats were placed prone to expose the left kidney area. After skin preparation, an oblique outward incision was m...

Embodiment 3

[0088] Example 3 (medicine efficacy test of wogonin prodrug on unilateral ureteral ligation (UUO) model rats)

[0089] 1. Purpose of the test: To investigate whether wogonin prodrug can improve renal fibrosis in 5 / 6 nephrectomy model rats.

[0090] 2. Test method: Taking wogonin ethyl ester (the hydrogen on the 7-hydroxyl group of wogonin is esterified) as an example, the method is the same as in Example 1.

[0091] 3. Test results: Wogonin prodrug can increase the weight of model rats, significantly inhibit the increase of serum creatinine and blood urea nitrogen content in chronic kidney disease animals, increase creatinine clearance rate, improve renal function; significantly reduce renal tissue hydroxyproline acid content.

[0092] 4. Experimental conclusion: Wogonin prodrug can improve renal fibrosis in unilateral ureteral ligation (UUO) model rats.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to wogonin and derivatives thereof, a prodrug of wogonin as well as medical use of wogonin and biologically-physiologically acceptable salts of wogonin and derivatives thereof for treating a chronic kidney disease, particularly for treating renal fibrosis and renal fibrosis-induced diseases.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to the medical application of wogonin. Specifically, the present invention relates to the medical application of wogonin and its derivatives, prodrugs and physiologically acceptable salts in the treatment of chronic kidney disease, especially in the treatment of chronic kidney disease. Medicinal use in renal fibrosis and diseases caused by renal fibrosis. Background technique [0002] Chronic kidney disease is one of the most common chronic refractory diseases. The annual incidence rate of chronic renal failure (CRF) in the natural population is 98-198 / 1 million population, and the incidence rate in developed countries such as the United States and Japan is as high as 8-10 million / 1 million population, showing an exponential upward trend in the past ten years. Chronic glomerulonephritis is still the main disease, but CRF caused by secondary factors is increasing year by year. Renal insuffici...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61P13/12
CPCA61K31/353A61P13/12
Inventor 张永煜孙淑军刘成海陶艳艳刘平戴建业曹慧娟房军伟郑宁宁
Owner SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap